SURVYR
13F +14% · EVERPOINT Institutional Filing Alert

EverPoint Asset Management (Point72 Arm) (Point72 Fundamental L/S Sub-Advisor) added to BSX (+14% shares QoQ · 17.5% of 13F portfolio)

Form 13F-HR institutional holdings disclosure · Filed 2026-10-16

EverPoint Holdings › All Filing Alerts › SEC Filing ↗

BSX

Boston Scientific Corporation
$42.43
−$2.63 (5.84%)Oct 28 close
Health CareS&P 500 CompareTechnicals
1M3M6M1Y2Y
-60%-41%-22%-4%+15%Oct 2025Oct 2026Apr 202652w high $105.6552w low $41.39
BSXSPY
Wall St. Highest PT $78.00 (+83.8%) Wall St. Avg PT $57.82 (+36.3%)
$42$58$74$90$107POC $44Hi $78Avg $58
Underwater Drawdown %Max DD -60.4%Current -59.6%
0.0%-60.4%
Relative Strength vs SPY-72.5% vs SPYUnderperforming
+85%0%-85%
1W
−$2.08 (4.67%)
1M
−$1.68 (3.81%)
3M
−$3.61 (7.84%)
6M
−$14.72 (25.76%)
YTD
−$52.92 (55.50%)
1Y
−$58.54 (57.98%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
30 analysts · mean score 1.60
1 = Strong Buy · 5 = Sell
Strong Buy620%
Buy1860%
Hold620%
Underperform00%
Sell00%
Wall Street consensus
Analyst price targets
Current price$42.43
Average target$57.82
+$15.39 (+36.3%) upsideaverage target vs current price
CurrentAverageMedian
Low$44.00
Median$56.00
High$78.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-26 · Stifel reiterated Buy on BSX
Reiterated
2026-10-14 · Truist Securities reiterated Buy on BSX
Initiated
2026-10-07 · Barclays started covering BSX at Equal-Weight
Reiterated
2026-10-05 · Citigroup reiterated Neutral on BSX
Reiterated
2026-09-24 · Wells Fargo reiterated Equal-Weight on BSX
Reiterated
2026-09-21 · Oppenheimer reiterated Outperform on BSX
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$65.3B
P/E (last 12 months)18.2
P/E (next 12 months, estimated)13.3
52-week range$41.39 – $105.65
Revenue growth (latest quarter vs a year ago)+7.5%
Dividend yieldNo dividend
Analyst consensusBuy (28)
Average analyst price target$57.82 (+36%)

What they do

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems.

Healthcare · Medical Devices
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
2nd percentile in sector
F
12-1 return: -56.7%
Percentile within its GICS sector across the S&P 1500.
Growth
45th percentile in sector
C
Revenue growth (YoY): +7.5%
Percentile within its GICS sector across the S&P 1500.
Value
69th percentile in sector
B
Forward E/P: 7.6% · EBITDA/EV: 7.4%
Percentile within its GICS sector across the S&P 1500.
Profitability
69th percentile in sector
B
Profit margin: +17.5% · Return on equity: +15.3%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Held by 1 of 7 live models: SURVYR. Barbell Momentum & T-Bill Shield.

SURVYR. Barbell Momentum & T-Bill Shield
5.0% of the book · Mid-Cap RS & EPS Leaders (75%) sleeve · ranked 9 of 160
 HeldQuality Growth
Outside this model's universe or screens
 Momentum Top 15
ranked 495 of 499 · 12-month momentum -50.5%
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book
Why it's in the SURVYR. Barbell Momentum & T-Bill Shield #9 of 160

Qualified on +31% 6M RS, category-defining electrophysiology organic growth. Ranked 9th of 160 at the 2026-10-01 rebalance.

What would knock it out: Drops out if it falls outside the top 16 at the next rebalance (Oct 30).

Earnings & events

BSX earningsNext report in -1 days
Next report · quarter Sep 2026
Wed Oct 28, 2026Before the open
EPS consensus$0.72 range $0.58–$0.82
Revenue consensus$5.1B 24 analysts
Last 4 quarters · EPS vs estimate
Jul 29, 2026$0.86est $0.83+3.9%Above estimates
Apr 22, 2026$0.80est $0.79+1.6%Above estimates
Feb 4, 2026$0.80est $0.78+2.4%Above estimates
Oct 22, 2025$0.75est $0.71+5.1%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-27 18:23:36 ET
24-1025-0225-0425-0725-1026-0226-0426-070.000.86
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$5.4B+7.5%
2026-03-31$5.2B–
2025-12-31$5.3B–
2025-09-30$5.1B–
2025-06-30$5.1B–

News & catalysts

More news
What Is Behind The Move In Boston Scientific Stock?
Trefis · 3h ago
What Have Medtronic Stock Holders Really Earned?
Trefis · 3h ago
Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Boston Scientific, eBay, Fervo Energy, Fortinet, Hilton Worldwide Holdings, Lennox International, Palantir Technologies, and More
24/7 Wall St. · 4h ago
Boston Scientific: 3 Key Takeaways for Long-Term Investors
Nasdaq · 12h ago
BSX after earnings: shares fell 5.8% on Oct 28
SURVYR. · 18h ago

Research

Coteau Barbell Momentum & T-Bill Shield: rebalance of Oct 1, 2026Oct 26, 2026
Rating changes
Reiterated
2026-10-26 · Stifel reiterated Buy on BSX
Reiterated
2026-10-14 · Truist Securities reiterated Buy on BSX
Initiated
2026-10-07 · Barclays started covering BSX at Equal-Weight
Reiterated
2026-10-05 · Citigroup reiterated Neutral on BSX
Reiterated
2026-09-24 · Wells Fargo reiterated Equal-Weight on BSX
Reiterated
2026-09-21 · Oppenheimer reiterated Outperform on BSX

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Morano Susan E
Director · 2026-08-25
Buy
$100.4K
Habiger David C
Director · 2026-08-05
Buy
$99.9K
Habiger David C
Director · 2026-08-04
Buy
$6.8K
Mahoney Michael F
Director, Chairman, President & CEO · 2026-08-03
Buy
$9.0M
Habiger David C
Director · 2026-08-03
Buy
$50.1K
Ludwig Edward J
Director · 2026-07-31
Buy
$227.4K
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-27 18:23:36 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026